Bronchiolitis is an important public health burden in the U.S. and worldwide. Indeed, bronchiolitis is the leading cause of hospitalizations in U.S. infants. However, to date, no specific treatment options for bronchiolitis exist.
One of the reasons for the lack of treatment options is the conventional wisdom — i.e., bronchiolitis is a homogeneous condition. However, our recent studies on bronchiolitis virology and airway microbiome have challenged this “wisdom”.
We combine insights from clinical medicine with advances in systems biology to phenoendotype infants with bronchiolitis and to develop targeted treatment options.